In conclusion, our data show—to our knowledge—the first prospective trial investigating aCNI-free GVHD prophylaxis regimen composed of the mTOR inhibitor everolimus and mycophenolate mofetil in the absence of additional GVHD preventing measures. Here, MTOR is linked to graft versus host disease.